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Disease relapse still remains the most important cause of treatment failure in childhood acute myeloid leukemia (AML). Molecular monitoring of response to treatment by minimal residual disease (MRD) provides remarkable information, widely used to tailor treatment in childhood acute lymphoblastic leukemia [1] [2] [3] . On the contrary, prognostic relevance of MRD in pediatric AML has been only recently proposed and needs to be further investigated and confirmed [4] [5] [6] . So far, the prognostic impact of the quality of response measured by flow-cytometry after induction and consolidation therapy has been shown to provide independent prognostic information in pediatric AML, 5 Ara-c) 7 . A larger than expected proportion of patients carrying either t(8;21) or inv (16) relapsed, this leading to a 8-year probability of event-free survival of 63%. Although many of the relapsing patients were rescued by means of allogeneic hematopoietic stem cell transplantation (HSCT) 8 , there is need to identify factors able to predict patients who might not respond to conventional chemotherapy to improve their outcome [9] [10] [11] .
In this retrospective study, we analyzed the role of MRD monitored by the absolute quantification of CBF fusion transcripts early during/after induction treatment, in order to assess its prognostic value in SR childhood AML. We enrolled 76 of the 99 children inv(16), and one t(16;16) (see Table 1 for details). MRD measurement on bone marrow samples collected at time of diagnosis and after each of the 2 courses of ICE induction chemotherapy were analyzed. It was not possible to study the remaining 23 SR patients due to insufficient RNA extracted from cells collected after induction courses, but the outcome of patients who were or were not included in the study was comparable (data not shown The number of transcript copies at diagnosis, or after induction therapy did not correlate with the probability of both survival and the CIR. We then considered the logarithmic reduction of MRD after ICE I and II courses calculated with respect to values of copies number of transcript found at diagnosis for each patient (Table 1S) . We subdivided patients in three Log-reduction groups: patients who reduced MRD less than 2 Log, between 2 and 3 Log, and those who reduced more than 3 Log in order to investigate whether this distribution into groups for MRD reduction was able to predict a different relapse risk. We interestingly found that 21 (43%) out of the 49 t(8;21) patients enrolled had a slow clearance of blasts after I ICE (< 2 Log with respect to diagnosis), and, at the end of the II ICE course, 10 of them still had a MRD reduction lower than 2 Log. These slow-responding t(8;21) patients at the end of the 2 induction courses had a worse prognosis when compared to patients who reduced MRD more than 3 Log (patients who reduced less than 2 Log showed a 10-year OS of only 58.3% compared to 85.6% of patients who reduced more than 3 Log, p = 0.2, Figure 1 ). Next, we investigated if MRD might influence the risk of relapse. Nine out of the 49 patients with t(8;21) relapsed at a median time of 225 days (range 76 to 469) from diagnosis: 7 out of the 9 relapsed t(8;21) patients reduced MRD less than 2 Log after I ICE, and 5 of these 9 relapsed patients still reduced MRD less than 2 Log at the end of the II induction course. The 10-year CIR of these patients after the two induction courses was significantly higher (50%) than that of patients with a MRD reduction greater than 2 Log (17% for 2-3 Log MRD reduction, and 9% for MRD Log reduction >3; Figure 2A I ICE p=0.02; 1B II ICE p=0.004). In univariate analysis both MRD log-reduction after induction therapy and white blood cell (WBC) count at diagnosis >100,000, as recently reported 8 , were significant independent factors predicting leukemia relapse; however, they were not confirmed in multivariate analysis, probably due to the limited sample size analyzed. In view of these data, we show that monitoring of molecular MRD levels is instrumental to predict the risk of relapse for t(8;21)-rearranged patients, thus providing important prognostic information for the therapeutic management of these children.
We then considered inv(16)-rearranged patients and performed similar analyses for the 27 patients enrolled. These patients showed a mean number of transcript copies at diagnosis of 143,015 (range from 102 to 582,426), which decreased to 631 (range from 0 to 3,726)
after the I ICE, and to 190 (range from 0 to 686) after the II ICE course, respectively. We evaluated if the copy number of fusion transcripts distributed in quartiles found in BM of patients at diagnosis, and at the end of the two ICE courses may have a prognostic value, but no significant differences were identified neither for CIR nor for OS in inv (16) rearranged patients ( Figure 1S ). Furthermore, by using the Log MRD reduction distribution, we found that
At time of last follow-up, 6/27 patients had relapsed; among them, we documented that MRD was reduced more than 2 Log since the end of I ICE. We conclude that the CBFB-MYH11 AML showed in most cases a rapid clearance of blasts after induction therapy. Thus, early MRD monitoring does not seem to be useful for predicting relapse occurrence ( Figure 2B , n o t s i g n i f i c a n t a t 1 0 y e a r s ).
Through this analysis, we document that among pediatric Core Binding Factor-rearranged AML two different patterns of molecular response after induction therapy with a different capacity of predicting relapse can be identified. In particular, we found that monitoring of MRD levels after induction provides a reliable prognostic parameter exclusively for the RUNX1-RUNX1T1-rearranged patients. These data confirm the clinical usefulness of monitoring MRD levels reported in a recent study on adults with RUNX1-RUNX1T1 AML, 14 although this report differs from our analysis in both timing (after 2 courses of consolidation therapy) and levels of MRD (3 log reduction) cut-off suggested to predict relapse. 
FIGURES LEGEND
Figure1: Overall Survival (OS) in RUNX1-RUNX1T1 patients subdivided into three classes of MRD Log reduction after two induction courses. Table 1S . Logarithmic (Log) reduction (Red) from the diagnosis in patients harboring the RUNX1-RUNX1T1.
If 0 copies were found the log reduction is not applicable (na) and patients were included into the MRD class reduction >3 Log. 
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